Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Psychopharmacology (Berl) ; 107(2-3): 303-9, 1992.
Article in English | MEDLINE | ID: mdl-1615130

ABSTRACT

Sibutramine hydrochloride, a novel monoamine reuptake inhibitor antidepressant, has been studied to determine whether it alters dopaminergic function in the brain. Its effects have been compared with bupropion, a dopamine reuptake inhibitor, and methamphetamine, a dopamine reuptake inhibitor and releasing agent. Sibutramine (0.1-3 mg/kg PO) and methamphetamine (0.3-30 mg/kg PO) both prevented reserpine (0.75 mg/kg IV) ptosis in rats with ED50 values of 0.6 mg/kg and 4.2 mg/kg, respectively. Bupropion (10-100 mg/kg PO) was ineffective against reserpine ptosis. The efflux of [3H]-dopamine from preloaded rat striatal slices was not altered by 10(-7)-10(-5) M concentrations of sibutramine, BTS 54,354, BTS 54,505 (secondary and primary amine metabolites, respectively) or bupropion. In contrast, methamphetamine (10(-8)-10(-4) M) caused a significant concentration-dependent increase in [3H]-dopamine release. Sibutramine (3 mg/kg IP or 6 mg/kg PO) and bupropion (10 mg/kg IP or 30 mg/kg PO) did not alter 3-methoxytyramine (3-MT) levels in rat striatum. Striatal 3-MT concentrations were, however, dose-dependently increased by methamphetamine (0.3-10 mg/kg IP or 0.42-4.2 mg/kg PO). Sibutramine (6 mg/kg PO) did not induce circling in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal dopaminergic neuronal tract. Bupropion (10-100 mg/kg PO) did not induce circling at the lowest dose, but caused increasing ipsilateral rotation at higher doses. Methamphetamine (0.42 or 4.2 mg/kg PO) induced ipsilateral circling with marked effects at the higher dose.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Antidepressive Agents/pharmacology , Bupropion/pharmacology , Cyclobutanes/pharmacology , Dopamine/physiology , Methamphetamine/pharmacology , Animals , Blepharoptosis/chemically induced , Blepharoptosis/prevention & control , Brain Chemistry/drug effects , Chromatography, High Pressure Liquid , Conditioning, Operant/drug effects , Corpus Striatum/metabolism , Corpus Striatum/physiology , Dopamine/analogs & derivatives , Dopamine/metabolism , Generalization, Psychological , Male , Rats , Reserpine , Stereotyped Behavior/drug effects , Substantia Nigra/physiology
2.
Neuropharmacology ; 29(12): 1141-50, 1990 Dec.
Article in English | MEDLINE | ID: mdl-2293058

ABSTRACT

3-Methoxytyramine (3-MT) is a minor metabolite of dopamine which is suggested to reflect the turnover and utilization of dopamine. A novel, isocratic HPLC method has been developed which can be used to analyse 3-MT in homogenates of rat brain without the need for additional purification procedures. Furthermore, the coulometric electrochemical detection system is sensitive enough to measure 3 pg of 3-MT (equivalent to 0.6 ng/g tissue wet weight). 3-Methoxytyramine was measured in the striatum and n. accumbens after decapitation and rapid freezing, using 3-methoxy-4-hydroxybenzylamine as the internal standard. The effects of dopaminergic and other drugs on this metabolite were examined using this method. alpha-Methyl-p-tyrosine (200 mg/kg i.v.) produced parallel linear decreases in dopamine and 3-MT in naive rats, but not those pretreated with tranylcypromine (5 mg/kg i.p.). Methamphetamine (0.3-10 mg/kg i.p.) and amphetamine (0.3-10 mg/kg i.p.) both dose-dependently increased 3-MT in naive and tranylcypromine-pretreated rats. In naive animals, 3-MT was not altered by intraperitoneal injection of the dopamine reuptake inhibitors, bupropion (10 mg/kg) and nomifensine (10 mg/kg) or by sibutramine HCl (3 mg/kg), amitriptyline (10 mg/kg), desipramine (10 mg/kg) and zimeldine (10 mg/kg). 3-Methoxytyramine was decreased by apomorphine (5 mg/kg i.p.) and also by large doses of the selective D2 antagonist, BRL 34778 (5 mg/kg i.p.) or L-DOPA (50 mg/kg i.p.). The selective D1 antagonist, SCH 23390 (0.1 or 5 mg/kg i.p.) was without effect. In tranylcypromine-pretreated rats, 3-MT was dose-dependently reduced and increased by apomorphine (0.01-5 mg/kg i.p.) and BRL 34778 (0.1-5 mg/kg i.p.), respectively. The drug SCH 23390 (0.1-5 mg/kg i.p.) produced much smaller increases in 3-MT which were probably mediated through the striatonigral pathway. Overall, the data suggest that measurement of 3-MT, after inhibition of monoamine oxidase, is a useful index of the release and utilization of dopamine. However, after substantial and prolonged depletion of dopamine, levels of 3-MT in naive animals are a better index. Also, the formation of 3-MT in naive rats rats provides a sensitive method for distinguishing between dopamine releasing agents and reuptake inhibitors.


Subject(s)
Brain/metabolism , Dextroamphetamine/pharmacology , Dopamine/analogs & derivatives , Dopamine/metabolism , Animals , Antidepressive Agents/pharmacology , Brain/drug effects , Chromatography, High Pressure Liquid/methods , Corpus Striatum/metabolism , Dopamine/analysis , Dopamine Antagonists , Electrochemistry/methods , Levodopa/pharmacology , Male , Methamphetamine/pharmacology , Methyltyrosines/pharmacology , Nucleus Accumbens/metabolism , Pargyline/pharmacology , Rats , Rats, Inbred Strains , Tranylcypromine/pharmacology , alpha-Methyltyrosine
SELECTION OF CITATIONS
SEARCH DETAIL
...